# Potential use of liquid biopsy in diagnosing oral malignancies

## TL;DR

Liquid biopsy offers a non-invasive way to detect and monitor oral cancers by analyzing biomarkers in blood, but challenges remain in standardization and cost.

## Contribution

The paper highlights the potential of liquid biopsy for early detection and monitoring of oral malignancies using ctDNA, CTCs, and exosomes.

## Key findings

- Liquid biopsy shows good sensitivity and specificity for detecting mutations and biomarkers in oral squamous cell carcinoma.
- Repeated sampling via liquid biopsy allows tracking of tumor burden and genetic changes over time.
- Challenges include standardization, biomarker validation, and cost-effectiveness for clinical use.

## Abstract

Liquid biopsy is a minimally invasive method with strong potential for detecting and monitoring oral cancers. By analyzing ctDNA,
CTCs, exosomes and other tumor-derived biomarkers, it enables early detection, prognosis and treatment monitoring. Unlike tissue biopsy,
it allows repeated sampling to track tumor burden and genetic changes over time. In oral squamous cell carcinoma, studies show good
sensitivity and specificity for detecting mutations, methylation and protein markers. However, standardization, biomarker validation and
cost-effectiveness remain challenges for clinical use.